β-amyloid burden is not associated with rates of brain atrophy

Annals of Neurology

Volumn 63, Issue 2, 2008, Pages 204-212

  Josephs, Keith A ^a   Whitwell, Jennifer L ^a   Ahmed, Zeshan ^b   Shiung, Maria M ^a   Weigand, Stephen D ^a   Knopman, David S ^a   Boeve, Bradley F ^a   Parisi, Joseph E ^a   Petersen, Ronald C ^a   Dickson, Dennis W ^b   Jack Jr , Clifford R ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN ATROPHY; BRAIN SIZE; BRAIN VENTRICLE; CLINICAL ARTICLE; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; GENOTYPE; GRAY MATTER; HUMAN; IMAGE ANALYSIS; MALE; NEUROFIBRILLARY TANGLE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROBABILITY; VASCULAR LESION; VOLUMETRY;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; ATROPHY; AUTOPSY; BRAIN; DISEASE PROGRESSION; FEMALE; GENOTYPE; HUMANS; LATERAL VENTRICLES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENILE PLAQUES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 40449135167     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21223     Document Type: Article

References (50)

1. Masters CL, Simms G, Weinman NA, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985;82:4245-4249.
2. Wimo A, Winblad B, Jonsson L. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimers Dement 2007;3:81-91.
3. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-185.
4. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177.
5. Gilman S, Koller M, Black RS, et al. Clinical effects of A{beta} immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-1562.
6. Jack CR Jr, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004;62:591-600.
7. Fox NC, Black RS, Gilman S, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005;64:1563-1572.
8. Archer HA, Edison P, Brooks DJ, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 2006;60:145-147.
9. Silbert LC, Quinn JF, Moore MM, et al. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 2003;61:487-492.
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington DC: American Psychiatric Association, 1994.
11. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
12. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
13. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
14. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997;18:S1-S2.
15. Crook R, Hardy J, Duff K. Single-day apolipoprotein E genotyping. J Neurosci Methods 1994;53:125-127.
16. Josephs KA, Tsuboi Y, Cookson N, et al. Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration. Arch Neurol 2004;61:1579-1584.
17. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
18. Braak H, Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl 1996;165:3-12.
19. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001;23:291-299.
20. Gunter JL, Shiung MM, Manduca A, et al. Methodological considerations for measuring rates of brain atrophy. J Magn Reson Imaging 2003;18:16-24.
21. Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging 1997;16: 623-629.
22. Bryan RN, Manolio TA, Schertz LD, et al. A method for using MR to evaluate the effects of cardiovascular disease on the brain: the cardiovascular health study. AJNR Am J Neuroradiol 1994;15:1625-1633.
23. Scheltens P, Barkhof F, Leys D, et al. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993;114:7-12.
24. Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318-1322.
25. Jack CR Jr, O'Brien PC, Rettman DW, et al. FLAIR histogram segmentation for measurement of leukoaraiosis volume. J Magn Reson Imaging 2001;14:668-676.
26. O'Brien PC. The appropriateness of analysis of variance and multiple-comparison procedures. Biometrics 1983;39:787-794.
27. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998;316:1236-1238.
28. Mirra SS, Gearing M, McKeel DW Jr, et al. Interlaboratory comparison of neuropathology assessments in Alzheimer's disease: a study of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD). J Neuropathol Exp Neurol 1994;53:303-315.
29. Yamaguchi H, Hirai S, Morimatsu M, et al. Diffuse type of senile plaques in the brains of Alzheimer-type dementia. Acta Neuropathol (Berl) 1988;77:113-119.
30. Dickson DW, Crystal HA, Mattiace LA, et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 1992;13:179-189.
31. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003;62: 1087-1095.
32. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007;64:431-434.
33. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-259.
34. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8:101-112.
35. Davis DG, Schmitt FA, Wekstein DR, et al. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 1999;58:376-388.
36. Lue LF, Kuo YM, Roher AE, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999;155:853-862.
37. Cummings BJ, Pike CJ, Shankle R, et al. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging 1996;17: 921-933.
38. Bussiere T, Friend PD, Sadeghi N, et al. Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer's disease. Neuroscience 2002;112:75-91.
39. Giannakopoulos P, Herrmann FR, Bussiere T, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003;60:1495-1500.
40. Arriagada PV, Growdon JH, Hedley-Whyte ET, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-639.
41. Bennett DA, Schneider JA, Wilson RS, et al. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 2004;61:378-384.
42. Gertz HJ, Xuereb J, Huppert F, et al. Examination of the validity of the hierarchical model of neuropathological staging in normal aging and Alzheimer's disease. Acta Neuropathol (Berl) 1998;95:154-158.
43. Brion JP, Flament-Durand J, Dustin P. Alzheimer's disease and tau proteins. Lancet 1986;2:1098.
44. Nagy Z, Jobst KA, Esiri MM, et al. Hippocampal pathology reflects memory deficit and brain imaging measurements in Alzheimer's disease: clinicopathologic correlations using three sets of pathologic diagnostic criteria. Dementia 1996;7:76-81.
45. Jack CR Jr, Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002;58:750-757.
46. Gosche KM, Mortimer JA, Smith CD, et al. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 2002;58:1476-1482.
47. Enzinger C, Fazekas F, Matthews PM, et al. Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology 2005;64:1704-1711.
48. Ishii K, Kawachi T, Sasaki H, et al. Voxel-based morphometric comparison between early- and late-onset mild Alzheimer's disease and assessment of diagnostic performance of z score images. AJNR Am J Neuroradiol 2005;26:333-340.
49. Wahlund LO, Julin P, Lannfelt L, et al. Inheritance of the ApoE epsilon4 allele increases the rate of brain atrophy in dementia patients. Dement Geriatr Cogn Disord 1999;10: 262-268.
50. Whitwell JL, Jack CR Jr, Parisi JE, et al. Rates of cerebral atrophy differ in different degenerative pathologies. Brain 2007; 130:1148-1158.